Aethlon Medical Announces Fiscal Third Quarter Financial Results and Provides Corporate Update

Core Viewpoint - Aethlon Medical, Inc. reported its financial results for the fiscal third quarter ended December 31, 2023, and provided updates on its ongoing research and clinical development efforts, particularly focusing on its Hemopurifier technology aimed at treating cancer and life-threatening infectious diseases [1][7]. Company Updates - Aethlon Medical is advancing the clinical development of its Hemopurifier, a blood filtration system designed to remove harmful exosomes and viruses, with potential applications in oncology and organ transplantation [2]. - The company received clearance from the Drug Controller General of India to conduct a phase 1 trial of the Hemopurifier in patients with solid tumors undergoing anti-PD-1 therapy [3]. - Aethlon is also maintaining its position in treating life-threatening viral infections through a COVID-19 trial in India, with one patient treated so far [5]. - The interim CEO emphasized a focus on the oncology program and cost reduction, with plans to publish preclinical data related to organ transplantation [6]. Financial Results - As of December 31, 2023, Aethlon Medical had a cash balance of approximately $8.0 million [7]. - Consolidated operating expenses for the third quarter were approximately $3.6 million, a 25.2% increase from $2.8 million in the same period in 2022, primarily due to increased payroll expenses [7][8]. - The net loss for the quarter increased to $3.6 million from $2.8 million year-over-year [9]. - The company reported a decrease in general and administrative expenses, but increases in payroll and related expenses, leading to a net loss of $3.6 million for the quarter [8][9].